Skip to content

AOCI at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$31.02M-7.2%
Arrowhead Research logo
Arrowhead ResearchARWR
$742K-83.1%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-$252K-163%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$8.47M+161%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$0+100%
Scholar Rock logo
Scholar RockSRRK
$690K+435%

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.35B+153%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s AOCI?
Dyne Therapeutics, Inc. (DYN) reported AOCI of -$137K in Q1 2026.
How has Dyne Therapeutics, Inc.'s AOCI changed year-over-year?
Dyne Therapeutics, Inc.'s AOCI decreased by 156.8% year-over-year, from $241K to -$137K.
What is the long-term trend for Dyne Therapeutics, Inc.'s AOCI?
Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s AOCI has grown at a 77.4% compound annual growth rate (CAGR), from -$27K to $475K.
What does AOCI mean?
Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.